🇺🇸 FDA
Pipeline program

Recombinant human tissue kallikrein

DM199-2017-001

Phase 2 small_molecule completed

Quick answer

Recombinant human tissue kallikrein for Acute Ischemic Stroke is a Phase 2 program (small_molecule) at DiaMedica Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
DiaMedica Therapeutics
Indication
Acute Ischemic Stroke
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials